CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh

As of June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh carries a market capitalization of 175.90B, placing it among publicly traded companies globally. Its enterprise value stands at 123.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh has 48.32B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 471.92, and the price-to-book ratio stands at 3.03.

These figures are as of June 30, 2026. The EV/Sales ratio of 337.57 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 123.38B versus a market cap of 175.90B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh maintains a current ratio of 17.85, meaning it holds 17.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh posted a negative return on equity (ROE) of -26.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.28, reflecting losses generated across the asset base. The company generates approximately 930,017.81 in revenue per employee across its workforce of 393.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh recorded 100.74M in income tax expense. The company reported a pretax loss of -14.89B and -14.99B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 21, 2026.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh generated 365.50M in revenue and converted that into -14.99B in net income, yielding earnings per share of -0.32. EBITDA reached -17.13B, while operating income came in at -17.75B.

As of June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh holds 78.56B in cash and equivalents against 26.04B in total debt, resulting in a net debt position of 9.80B. Total book value stands at 58.03B, with working capital of 74.39B providing operational flexibility.

CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh produced -12.28B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -57.91M in capital expenditures, free cash flow totaled -12.34B - equivalent to -0.26 per share.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh posted a gross margin of -1,691.26, reflecting its pricing power and cost economics. The operating margin of -4,857.64 and net profit margin of -4,101.26 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -19.12, meaning CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, CRISPR Therapeutics AG Shs Thailand Depositary Receipts Repr 1 Sh has an Altman Z-Score of 2.72, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.